Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.86 |
| ▸ | KDM6B | O15054 | 3/20 | 0.86 |
| ▸ | KDM5C | P41229 | 3/20 | 0.86 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.86 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.86 |
| ▸ | KDM3A | Q9Y4C1 | 3/20 | 0.86 |
| ▸ | JMJD6 | Q6NYC1 | 8/20 | 0.73 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL70279 | 1.00 | KDM4E (0.86) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL6514670 | 0.98 | KDM4E (0.83) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| Hydrochloric Acid SCHEMBL6504834 | 0.98 | KDM4E (0.83) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL714108 | 0.93 | KDM4E (0.76) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL2868531 | 0.93 | KDM5C (1.00) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL30774379 | 0.93 | KDM4E (0.76) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL19229659 | 0.93 | KDM4E (0.76) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL29670732 | 0.93 | KDM5C (1.00) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL14944871 | 0.91 | KDM4E (0.73) | KDM4EKDM6BKDM5CKDM4CKDM2A | |
| SCHEMBL7033789 | 0.90 | KDM4E (0.71) | KDM4EKDM6BKDM5CKDM4CKDM2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | claimed |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | THERALASE TECHNOLOGIES, INC. (CA) | 2025-04-10 | — | — | US | claimed |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2026-01-01 | — | — | US | disclosed |
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | disclosed |
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | THERALASE TECH INC (CA) | 2025-12-11 | — | — | US | disclosed |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2025-09-04 | — | — | US | disclosed |
| EP-4558513-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | Merck Sharp & Dohme LLC (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4536650-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4536658-A1 | 1,8-NAPHTHYRIDIN-2-ONE HETEROBIFUNCTIONAL BCL6 DEGRADERS | Treeline Biosciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | THERALASE TECHNOLOGIES, INC. (CA) | 2025-04-10 | — | — | US | disclosed |
| WO-2025003315-A1 | POLYMERIZABLE COMPOSITION OF CYCLIC OLEFINIC MONOMERS AND ASSOCIATED RING-OPENING METATHESIS POLYMERIZATION PROCESS | TELENE SAS (FR) | 2025-01-02 | — | — | WO | disclosed |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. | 2024-08-29 | — | — | US | disclosed |
| CN-118176175-A | Method for producing perfluoroalkyl group-containing aromatic compound | 大金工业株式会社 | 2024-06-11 | — | — | CN | disclosed |
| WO-2024020159-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | MERCK SHARP & DOHME LLC (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023074510-A1 | METHOD FOR PRODUCING PERFLUOROALKYL GROUP-CONTAINING AROMATIC COMPOUND | ダイキン工業株式会社 | 2023-05-04 | — | — | WO | disclosed |
| CN-115124677-A | Meltable metal organic framework material and covalent organic framework material, preparation method and application thereof | 首都师范大学 | 2022-09-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250375458-A1 | COMPOSITIONS AND METHODS TO COMBAT MULTIDRUG-RESISTANT AND PERSISTENT T-CELL-MEDIATED, ONCOLOGICAL AND INFECTIOUS DISEASES | CD4, TPMT, SLC11A2 | KDM4E 691/4885KDM6B 1996/4885KDM5C 3176/4885 |
| US-20240287091-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | KDM4E 800/4885KDM6B 362/4885KDM5C 945/4885 |
| US-20250276981-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | BCL6, BCL6B, BCOR | KDM4E 800/4885KDM6B 362/4885KDM5C 945/4885 |
| US-20250114456-A1 | ENHANCED IMMUNOTHERAPEUTIC METHOD COMPRISING COMBINED ADMINISTRATION OF PHOTODYNAMIC / RADIOTHERAPEUTIC COMPOUNDS AND IMMUNOTHERAPEUTIC AGENTS | PDCD1, CD47, CD274 | KDM4E 3697/4885KDM6B 3075/4885KDM5C 3817/4885 |
| US-20260001914-A1 | MACROCYCLIC PEPTIDES TARGETING KRAS | KRAS, NRAS, HRAS | KDM4E 3980/4885KDM6B 4206/4885KDM5C 2274/4885 |
| US-20250375511-A1 | METHOD FOR TREATING CONDITIONS ASSOCIATED WITH HYPERPROLIFERATING CELLS COMPRISING COMBINED ADMINISTRATION OF INFECTIOUS AGENTS AND METAL CATIONS | NFATC1, PCNA, PHPT1 | KDM4E 4568/4885KDM6B 4815/4885KDM5C 4772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.